March 01, 2011
The owners of a retail drug chain filed an antitrust class action Tuesday accusing Astellas Pharma US Inc. of abusing the U.S. Food and Drug Administration's drug approval process to delay a generic version of Prograf and corner the market for the immunosuppressant.